• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16732 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     NIHR Health Services and Delivery Research programme Peer support for adult social care in prisons in England and Wales: a mixed-methods rapid evaluation
2025     NIHR Health Technology Assessment programme Multi-cancer early detection tests for general population screening: a systematic literature review
2025     NIHR Health Technology Assessment programme Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study
2025     National Institute for Health and Care Excellence (NICE) Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE interventional procedures guidance 798
2025     National Institute for Health and Care Excellence (NICE) Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults. NICE interventional procedures guidance 799
2025     National Institute for Health and Care Excellence (NICE) Tebentafusp for treating advanced uveal melanoma. NICE technology appraisal guidance 1027
2025     National Institute for Health and Care Excellence (NICE) Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1030
2025     National Institute for Health and Care Excellence (NICE) Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal). NICE technology appraisal guidance 1029
2025     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal). NICE technology appraisal guidance 1028
2025     National Institute for Health and Care Excellence (NICE) Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over. NICE technology appraisal guidance 1031
2025     National Institute for Health and Care Excellence (NICE) Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours. NICE technology appraisal guidance 1034
2025     National Institute for Health and Care Excellence (NICE) Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal). NICE technology appraisal guidance 1032
2025     National Institute for Health and Care Excellence (NICE) Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease. NICE technology appraisal guidance 1035
2025     NIHR Health Technology Assessment programme Public and patient involvement (PPI) in the design, execution and dissemination of a trial: the BISTRO trial
2025     NIHR Health Technology Assessment programme A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
2025     NIHR Health and Social Care Delivery Program Systematic review of integrated mental and physical health services for children and young people with eating and functional symptoms
2025     Belgian Health Care Knowledge Centre (KCE) Cost-effectiveness of new preventive options against RSV infections in Belgian infants
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Newborn screening for Metachromatic leukodystrophy (MLD)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions to formal caregivers for increased patient safety]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Digital technology promoting health for children and adolescents - an evidence map]
2025     Health Information and Quality Authority (HIQA) HTA of providing a telephone service for acute, non-urgent medical care needs in the pre-hospital setting
2025     Scottish Health Technologies Group (SHTG) Artificial intelligence-assisted clinician review of chest X-rays for suspected lung cancer
2025     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for the treatment of people with symptomatic severe aortic stenosis who are at low surgical risk
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2024     Malaysian Health Technology Assessment (MaHTAS) Computer aided-detection or artificial intelligence for chest X-ray in early detection of tuberculosis
2024     Malaysian Health Technology Assessment (MaHTAS) Deep brain stimulation (DBS) for advanced Parkinson’s disease - an update
2024     Malaysian Health Technology Assessment (MaHTAS) Handheld fundus camera - an update
2024     Malaysian Health Technology Assessment (MaHTAS) Breath test for tuberculosis
2024     Malaysian Health Technology Assessment (MaHTAS) Podoscope for footprint analysis
2024     Malaysian Health Technology Assessment (MaHTAS) Transcranial direct current stimulation (tDCS) for depression and schizophrenia
2024     Malaysian Health Technology Assessment (MaHTAS) Ethos therapy for cancer patient
2024     Malaysian Health Technology Assessment (MaHTAS) Wide field digital eye imaging system for universal neonatal eye screening
2024     Malaysian Health Technology Assessment (MaHTAS) Whole exome sequencing for children with suspected genetic disease
2024     Malaysian Health Technology Assessment (MaHTAS) Hair follicles as epigenetic biomarkers for assessing wellbeing
2024     NIHR Health Technology Assessment programme Evidence of quality of life for hospitalised patients with COVID-19: a scoping review
2024     WorkSafeBC Compartment syndrome and collagen structure
2024     WorkSafeBC Risk factors associated with the development or acceleration of degenerative disc disease for helicopter pilots - 2024 update
2024     WorkSafeBC Low-dose naltrexone as treatment for post-Covid conditions: first update
2024     WorkSafeBC COVID-19 and multiple sclerosis relapse
2024     WorkSafeBC Best practices for preventing psychological injury to front-line community support workers
2024     WorkSafeBC Restless legs syndrome (RLS) and post-traumatic stress disorder (PTSD): 2024 update
2024     WorkSafeBC Dance movement therapy as treatment for post-traumatic stress disorder (PTSD)
2024     WorkSafeBC Causal association on the development of transverse myelitis post mRNA Covid-19 vaccination
2024     WorkSafeBC Colon cancer and firefighting
2024     WorkSafeBC Causal association of neuroendocrine tumors and work duties as a firefighter
2024     WorkSafeBC Pharmacological and psychosocial interventions for ketamine use disorder
2024     WorkSafeBC Efficacy/effectiveness of prolozone or PEMF in treating shoulder or back strain as well as disc herniation
2024     WorkSafeBC Causal association between exposure to certain chemicals and the development of idiopathic Parkinson's Disease
2024     WorkSafeBC Causal association of being a retired firefighter and the development of coronary artery diseases (CAD)
2024     WorkSafeBC Causal association between back sprain / strain and spontaneous abortion
2024     WorkSafeBC Efficacy and effectiveness of cold compression therapies post-joint surgery
2024     WorkSafeBC Causal association between post-concussion syndrome and the development of myalgic encephalomyelitis / chronic fatigue syndrome
2024     WorkSafeBC Efficacy / effectiveness of platelet-rich plasma in treating chronic ankle sprain
2024     WorkSafeBC Efficacy / effectiveness of platelet rich plasma in treating Sinus Tarsi Syndrome
2024     WorkSafeBC Safety and efficacy / effectiveness on the placement of permanent catheter for marcaine infusion to treat radial nerve injury post-de Quarvain tenosinovitis surgery: 2024 update
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Vygon App – training platform for Vygon products
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Terve Päivä – digital lifestyle guidance
2024     Institute of Health Economics (IHE) Continuing care design standards to accommodate aging in place in Alberta: rapid review
2024     Institute of Health Economics (IHE) Strategies for optimizing patient flow through the intensive care unit
2024     Institute of Health Economics (IHE) Current and future investments for reaching the UNAIDS 95-95-95 HIV targets in Canada: evidence review & cost analysis
2024     Institute of Health Economics (IHE) Mammography screening for breast cancer: a replication of a systematic review of observational studies to inform an update of the Canadian Task Force on Preventive Health Care guidelines
2024     Institute of Health Economics (IHE) Patient initiated follow up in ambulatory secondary care
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non-small cell lung cancer
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma
2024     Agency for Care Effectiveness (ACE) Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2024     Agency for Care Effectiveness (ACE) Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
2024     Agency for Care Effectiveness (ACE) Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
2024     Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2024     Agency for Care Effectiveness (ACE) Selexipag for treating pulmonary arterial hypertension
2024     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
2024     Agency for Care Effectiveness (ACE) Burosumab for treating X-linked hypophosphataemia
2024     Agency for Care Effectiveness (ACE) Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine
2024     Agency for Care Effectiveness (ACE) Enzyme replacement therapies for Fabry disease
2024     Agency for Care Effectiveness (ACE) Nusinersen and risdiplam for treating spinal muscular atrophy
2024     Agency for Care Effectiveness (ACE) Ruxolitinib for treating graft-versus-host disease
2024     Agency for Care Effectiveness (ACE) Tolvaptan for treating autosomal dominant polycystic kidney disease
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating Wolman disease. NICE highly specialised technologies guidance 30
2024     National Institute for Health and Care Excellence (NICE) Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome. NICE highly specialised technologies guidance 31
2024     Agency for Care Effectiveness (ACE) Cervical artificial disc replacement for treatment of patients with cervical disc degenerative disease
2024     Agency for Care Effectiveness (ACE) Continuous glucose monitoring systems for children and adults with type 1 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Lumbar artificial disc replacement for treatment of patients with lumbar disc degenerative disease
2024     Agency for Care Effectiveness (ACE) Radiolucent fixation rods & screws for patients with primary and metastatic spinal tumours
2024     Agency for Care Effectiveness (ACE) Tricuspid transcatheter edge-to-edge repair system for symptomatic severe tricuspid regurgitation
2024     Agency for Care Effectiveness (ACE) FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2024     Agency for Care Effectiveness (ACE) Oxevision for vision-based patient monitoring and management in mental health wards
2024     Agency for Care Effectiveness (ACE) KidneyIntelX for patients with diabetic kidney disease
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease